Trials / Conditions / Castration Resistant Prostate Cancer (CRPC)

Castration Resistant Prostate Cancer (CRPC)

11 registered clinical trials studyying Castration Resistant Prostate Cancer (CRPC) — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors NCT07189871	Radiopharm Theranostics, Ltd	Phase 1 / Phase 2
Not Yet Recruiting	A Clinical Study Evaluating the Safety and Efficacy of Local Injection of ACT#001 Chimeric Antigen Receptor T NCT07240857	Zhejiang University	EARLY_Phase 1
Not Yet Recruiting	Imaging of Solid Tumors Using DLL3 SPECT NCT07052760	Thomas Hope	EARLY_Phase 1
Terminated	Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (M NCT06287463	Deciphera Pharmaceuticals, LLC	Phase 1
Terminated	Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC-PC) NCT04615845	Pharmicell Co., Ltd.	Phase 1
Terminated	A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-862 NCT02698176	Merck Sharp & Dohme LLC	Phase 1
Completed	A Study to Determine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPC NCT02669147	Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan	—
Completed	A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dos NCT01911741	Astellas Pharma Europe B.V.	Phase 1
Completed	A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showe NCT01534052	Astellas Pharma Inc	Phase 2
Completed	Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates NCT01911728	Astellas Pharma Europe B.V.	Phase 1
Completed	A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patie NCT01284920	Astellas Pharma Inc	Phase 1 / Phase 2